Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
COVID-19 is causing a serious viral pandemic in terms of health and social impact. To date,
no treatment has yet demonstrated Strong efficacy in treating the infectious disease
(COVID-19). Pulmonary administration of Interferon (IFN) type I is a therapeutic strategy
with high potential,due to higher local concentrations and minimal adverse effects. Type I
interferons (including IFN-α and IFN-β) are antiviral defence cytokines and also have the
potential to negatively modulate IFN Type II and IL-6 dependent cytokine storm, the latter
being induced in the late forms of COVID-19. In vitro, IFN-β were more effective on COVID-19
than IFN-α. In existing preliminary studies, only patients receiving IFN type I modulators
have a decrease in viral carriage and a rapid reversal. The purpose of this project is to
assess in hospitalized patients with oxygen for COVID 19, the clinical efficacy on oxygen
requirements of the addition of inhaled Interferon type I compared to the control arm .